206 related articles for article (PubMed ID: 37586766)
21. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
22. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
23. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
[TBL] [Abstract][Full Text] [Related]
24. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.
Chung MW; Kim MJ; Won EJ; Lee YJ; Yun YW; Cho SB; Joo YE; Hwang JE; Bae WK; Chung IJ; Shin MG; Shin JH
World J Gastroenterol; 2021 Nov; 27(42):7340-7349. PubMed ID: 34876793
[TBL] [Abstract][Full Text] [Related]
25. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Saini A; Wallace A; Alzubaidi S; Knuttinen MG; Naidu S; Sheth R; Albadawi H; Oklu R
J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30621040
[TBL] [Abstract][Full Text] [Related]
26. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
28. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
29. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
31. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.
Sangro B; Bilbao JI; Boan J; Martinez-Cuesta A; Benito A; Rodriguez J; Panizo A; Gil B; Inarrairaegui M; Herrero I; Quiroga J; Prieto J
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):792-800. PubMed ID: 16904840
[TBL] [Abstract][Full Text] [Related]
32. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
33. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
Fessas P; Kaseb A; Wang Y; Saeed A; Szafron D; Jun T; Dharmapuri S; Rafeh Naqash A; Muzaffar M; Navaid M; Khan U; Lee C; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Benevento F; Hildebrand H; Pressiani T; Abugabal YI; Personeni N; Huang YH; Rimassa L; Ang C; Marron T; Pinato DJ
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868393
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
35. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab for the treatment of hepatocellular carcinoma.
Finkelmeier F; Waidmann O; Trojan J
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
[TBL] [Abstract][Full Text] [Related]
37. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
38. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
Lee EW; Alanis L; Cho SK; Saab S
Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma.
Yu JI; Lee SJ; Lee J; Lim HY; Paik SW; Yoo GS; Choi C; Park HC
Cancer Med; 2019 Nov; 8(16):6986-6994. PubMed ID: 31588679
[TBL] [Abstract][Full Text] [Related]
40. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
